🧠 Multiple Sclerosis Therapeutic Vaccine Tracker

Updated July 2026. Big MS-EBV development: A Phase 2 trial testing an experimental EBV mRNA vaccine for safety in early MS launched in November 2025 — open to people with clinically isolated syndrome, relapsing-remitting MS, active secondary progressive MS, and radiologically isolated syndrome. The trial is expected to conclude in 2029. Meanwhile, Moderna's mRNA-1189 (EBV prophylactic vaccine) Phase 1/2 Eclipse trial (NCT05164094) involving ~850 adults and adolescents across 24+ US sites has results expected October 2025. A parallel Phase 1 launched in Australia in March 2025 (results May 2027). Moderna also started a new Phase 1 study of mRNA-1189 (NCT07478952, healthy adults 18–30) in March 2026, evaluating intradermal vs intramuscular delivery. Companion candidate mRNA-1195 (Phase 1, NCT05831111, 18–55 healthy adults) completes October 2026. An NIH-run Phase 1/2 study of an adjuvanted EBV gp350-ferritin nanoparticle vaccine (NCT05683834, 25 EBV-naive participants) reports preliminary results in April 2026. All are riding the 2022 Science landmark showing EBV infection increases MS risk 32-fold — the strongest environmental risk factor identified.

Comprehensive tracking of Multiple Sclerosis (MS) therapeutic vaccine development targeting myelin antigens for immune tolerance, Epstein-Barr virus (EBV), and autoimmune pathways. MS affects 1 million US adults, 2.8 million globally. Autoimmune disease causing progressive neurological disability through CNS demyelination. Therapeutic vaccines aim to induce immune tolerance to myelin proteins, prevent relapses, slow disability progression. Multiple Phase 2/3 trials target myelin basic protein (MBP), proteolipid protein (PLP), myelin oligodendrocyte glycoprotein (MOG), and EBV. DNA vaccines, peptide tolerance induction, and anti-viral approaches show promise. Complementary to disease-modifying therapies (DMTs) and lifestyle management.

⚠️ PROGRESSIVE NEUROLOGICAL DISABILITY:

Multiple Sclerosis affects 1 million Americans, 2.8 million globally. Autoimmune disease attacking CNS myelin causing vision loss, weakness, numbness, cognitive impairment, bladder dysfunction, progressive disability. Most common non-traumatic neurological disability in young adults (peak onset 20-40 years). Women affected 2-3x more than men. 85% start with relapsing-remitting MS (RRMS), eventually progressing to secondary progressive MS (SPMS) in 50%. Primary progressive MS (PPMS) 15%. Average life expectancy reduced 5-10 years. Current DMTs reduce relapses 30-70% but don't cure or fully prevent progression. Therapeutic vaccines offer hope for immune tolerance, disease modification.

MS Vaccines by Development Phase